Nostics, a startup in the medical diagnostics field, has appointed Jeroen Nieuwenhuis, an experienced medtech entrepreneur, as its new CEO. With the company’s plans to launch its innovative diagnostics technology in the point-of-care market, the addition of Jeroen is a significant step forward for Nostics.
Nostics has developed a diagnostic platform that combines Raman spectroscopy, nanotechnology, and AI-based classification to provide rapid infectious disease diagnostics, with a focus on bacterial infections. The aim is to combat antibiotic resistance by guiding effective antibiotic treatment, particularly in primary care facilities, labs, and hospitals where antibiotics are most prescribed. With Jeroen joining the team, Nostics has gained a valuable asset with over 15 years of experience in in-vitro diagnostics, particularly in point-of-care diagnostics. Jeroen has successfully led the spinout of the Minicare technology from Philips, which enables swift point-of-care heart attack diagnosis, and developed a second-generation product later acquired by Siemens Healthineers.
With Jeroen at the helm, Nostics gains an experienced leader with a forward-thinking vision. He plans to further develop the company’s already impressive technical achievements and create a strong diagnostics platform that can serve a wide range of needs in the infectious disease field. His ultimate goal is to create a platform that can tackle current challenges and adapt to emerging threats in the future.
On becoming part of the Nostics team, Jeroen shares: “Armed with a promising technology and a passionate team, I am excited to embark on the journey to take Nostics’ platform from bench to market together.”
Jeroen is joining the management team with co-founders Eva Rennen, Rochelle Niemeijer and Vincent Laban, next to Bob de Vos (Lead AI). Vincent (former CEO, now CFO) concludes: “I am extremely pleased to welcome Jeroen as our new CEO. The success of Minicare over the last years has been inspiring. We strive to create similar breakthroughs in infectious disease diagnostics, and Jeroen’s background makes him the ideal candidate to lead Nostics through the next phase.”
